These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

120 related items for PubMed ID: 23478543

  • 1. Review of ongoing clinical trials in non-small-cell lung cancer: a status report for 2012 from the ClinicalTrials.gov Web site.
    Subramanian J, Regenbogen T, Nagaraj G, Lane A, Devarakonda S, Zhou G, Govindan R.
    J Thorac Oncol; 2013 Jul; 8(7):860-5. PubMed ID: 23478543
    [Abstract] [Full Text] [Related]

  • 2. Review of ongoing clinical trials in non-small cell lung cancer: a status report for 2009 from the ClinicalTrials.gov website.
    Subramanian J, Madadi AR, Dandona M, Williams K, Morgensztern D, Govindan R.
    J Thorac Oncol; 2010 Aug; 5(8):1116-9. PubMed ID: 20592626
    [Abstract] [Full Text] [Related]

  • 3. Biomarkers and receptor targeted therapies reduce clinical trial risk in non-small-cell lung cancer.
    Falconi A, Lopes G, Parker JL.
    J Thorac Oncol; 2014 Feb; 9(2):163-9. PubMed ID: 24419412
    [Abstract] [Full Text] [Related]

  • 4. Accrual to National Cancer Institute-sponsored non-small-cell lung cancer trials: insights and contributions from the CCOP program.
    Lyss AP, Lilenbaum RC.
    Clin Lung Cancer; 2009 Nov; 10(6):410-3. PubMed ID: 19900858
    [Abstract] [Full Text] [Related]

  • 5. A Brief Report of the Status of Central Nervous System Metastasis Enrollment Criteria for Advanced Non-Small Cell Lung Cancer Clinical Trials: A Review of the ClinicalTrials.gov Trial Registry.
    McCoach CE, Berge EM, Lu X, Barón AE, Camidge DR.
    J Thorac Oncol; 2016 Mar; 11(3):407-13. PubMed ID: 26725180
    [Abstract] [Full Text] [Related]

  • 6. The changing landscape of phase II/III metastatic NSCLC clinical trials and the importance of biomarker selection criteria.
    Gentzler RD, Yentz SE, Johnson ML, Rademaker AW, Patel JD.
    Cancer; 2014 Dec 15; 120(24):3853-8. PubMed ID: 25155290
    [Abstract] [Full Text] [Related]

  • 7. Elderly patients with advanced NSCLC in phase III clinical trials: are the elderly excluded from practice-changing trials in advanced NSCLC?
    Sacher AG, Le LW, Leighl NB, Coate LE.
    J Thorac Oncol; 2013 Mar 15; 8(3):366-8. PubMed ID: 23407560
    [Abstract] [Full Text] [Related]

  • 8. Potential role for epidermal growth factor receptor inhibitors in combined-modality therapy for non-small-cell lung cancer.
    Kim DW, Choy H.
    Int J Radiat Oncol Biol Phys; 2004 Mar 15; 59(2 Suppl):11-20. PubMed ID: 15142630
    [Abstract] [Full Text] [Related]

  • 9. Management of unresectable stage III non-small-cell lung cancer with combined-modality therapy: a review of the current literature and recommendations for treatment.
    Bayman NA, Blackhall F, Jain P, Lee L, Thatcher N, Faivre-Finn C.
    Clin Lung Cancer; 2008 Mar 15; 9(2):92-101. PubMed ID: 18501095
    [Abstract] [Full Text] [Related]

  • 10. The clinical development of molecularly targeted agents in combination with radiation therapy: a pharmaceutical perspective.
    Ataman OU, Sambrook SJ, Wilks C, Lloyd A, Taylor AE, Wedge SR.
    Int J Radiat Oncol Biol Phys; 2012 Nov 15; 84(4):e447-54. PubMed ID: 22819210
    [Abstract] [Full Text] [Related]

  • 11. Is there a role for cetuximab in non small cell lung cancer?
    Morgensztern D, Govindan R.
    Clin Cancer Res; 2007 Aug 01; 13(15 Pt 2):s4602-5. PubMed ID: 17671149
    [Abstract] [Full Text] [Related]

  • 12. Analysis of lung cancer patients enrolled in CTEP (cancer therapy evaluation program)-sponsored phase I trials.
    Gadgeel SM, Ivy P, Chen W, Mauer J, Smith D, Lorusso P.
    Clin Lung Cancer; 2011 Jul 01; 12(4):218-23. PubMed ID: 21726820
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. A trial of autologous ex vivo-expanded NK cell-enriched lymphocytes with docetaxel in patients with advanced non-small cell lung cancer as second- or third-line treatment: phase IIa study.
    Yang YJ, Park JC, Kim HK, Kang JH, Park SY.
    Anticancer Res; 2013 May 01; 33(5):2115-22. PubMed ID: 23645763
    [Abstract] [Full Text] [Related]

  • 15. Targeted therapy for the treatment of advanced non-small cell lung cancer: a review of the epidermal growth factor receptor antagonists.
    Silvestri GA, Rivera MP.
    Chest; 2005 Dec 01; 128(6):3975-84. PubMed ID: 16354869
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients.
    Roengvoraphoj M, Tsongalis GJ, Dragnev KH, Rigas JR.
    Cancer Treat Rev; 2013 Dec 01; 39(8):839-50. PubMed ID: 23768755
    [Abstract] [Full Text] [Related]

  • 18. Necitumumab in the treatment of advanced non-small cell lung cancer: translation from preclinical to clinical development.
    Dienstmann R, Felip E.
    Expert Opin Biol Ther; 2011 Sep 01; 11(9):1223-31. PubMed ID: 21679088
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Erlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cancer.
    Smith J.
    Clin Ther; 2005 Oct 01; 27(10):1513-34. PubMed ID: 16330289
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.